NEJM publishes results from phase 2 study of vaccines reducing TB infections
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Aurinia Pharmaceuticals: AURORA 1 Phase 3 study results published in The Lancet
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Rezolute announces study results from Phase 1a of RZ402
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Sarepta reports clinical results from Phase 2 MOMENTUM study of SRP-5051
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Inovio sinks 26% after US government decides to discontinue funding for next phase of COVID-19 vaccine trial
"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines," said Inovio in a st.....»»
Sorrento Therapeutics announces results of Phase 1b study of COVI-MSC treatment
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Jazz Pharma announces results from Phase 3 study of XywavTM oral solution
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Alnylam announces full "positive" results from HELIOS-A Phase 3 study
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Compass Pathways announces COMP360 psilocybin study results published in NEJM
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Results in Endo"s phase 3 study show meaningful improvement in severe cellulite
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
CDC director says data "suggests that vaccinated people do not carry the virus"
On Monday, the CDC released a study using real-world evidence, which showed that mRNA vaccines are 90% effective at preventing COVID-19 infections. Director of the Centers for Disease Control Rochelle Walensky speaking at a White House press .....»»
Lyra Therapeutics to present LANTERN Phase 2 Study Results for LYR-210
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Myovant Sciences, Pfizer report "positive" results from Phase 3 Liberty study
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Alnylam to present full 9-month results from HELIOS-A Phase 3 study at AAN
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Strongbridge presents results from Pivotal Phase 3 LOGICS Study of RECORLEV
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Incyte"s Ruxolitinib Fails To Beat Placebo In Improving Mortality In Critically-Ill COVID-19 Patients
Incyte Corporation NASDAQ: INCY) announced results from the Phase 3 DEVENT study evaluating two doses of ruxolitinib (5mg and 15mg) plus standard of care (SoC) versus SoC in patients read more.....»»
Gamida Cell presents efficacy results from Phase 3 omidubicel study
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Inhibrx"s INBRX-105 Shows Dose-Limiting Toxicities In Early-Stage Solid Tumors Study
Inhibrx Inc (NASDAQ: INBX) has announced results from the dose escalation of the Phase 1 study evaluating INBRX-105 in locally advanced or metastatic solid tumors. INBRX-105 is a pre.....»»
VBI Vaccines begins enrollment of Phase 1/2 clinical study of VBI-2902
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Alligator Bioscience AB: Year-end Report January-December 2020
STOCKHOLM, Feb. 26, 2021 /PRNewswire/ -- "Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with metastatic cancer. The results show a promising safety profile w.....»»
Eiger BioPharma announces results from Phase 2 PREVENT study of Avexitide
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»